Pangaea is working with two well respected community-based HIV programs in Oakland, the California Prevention and Education Project (CAL-PEP)and La Clinica de la Raza, alongside the University of California, Berkeleyand theAlameda County Public Health Department Office of AIDS, to explore reasons for late testing and delayed entry into care for HIV/AIDS in Oakland, California and define solutions to address this critical issue. This research project is being funded by the National Institutes of Health, Office of AIDS Research.
Dr. Barrot Lambdin joined Pangaea in 2010 as Director of Implementation Science to lead research and evaluation efforts in support of Pangaea's programs. At this stage of the global response to HIV/AIDS, the international HIV community is increasingly focused on using implementation science to understand why interventions are not accessed by those who need them and how to improve the efficiency and effectiveness of service delivery.
These efforts can ultimately provide the basis for expanding access to HIV prevention and treatment for most-at-risk populations. Bringing Barrot on board is part of Pangaea's commitment to working with our partners to develop solutions that work.
Since November 2010, Pangaea has been assisting UNAIDS/ WHO in the development and implementation of Treatment 2.0 – the UNAIDS/WHO initiative launched in July 2010 focused on “catalysing the next phase of HIV treatment, care & support”.“After 30 years of responding to AIDS, the global community has reached a new ‘tipping point’,”said Pangaea CEO Ben Plumley. “With UNAIDS and WHO leading the way, we have the opportunity – and responsibility – through Treatment 2.0 to bring advances in HIV treatment to everyone who needs them.”
Pangaea is pleased to welcome Hany Adawalla, Richard Davis and Deary Paul Duffie to the Board of Directors. “I am very pleased Hany, Richard and Deary are joining the committed and talented individuals of the Pangaea board,” said Pangaea CEO Ben Plumley. “They bring a wealth of experience and expertise to the board at a time when Pangaea is expanding its impact in the global fight against HIV.”
Hany Adawalla is Managing Director of Rodmen & Renshaw, leading the firm’s healthcare investment banking team. He has assisted companies with financial and strategic advice for almost 25 years, serving as head of healthcare at investment banking firms such as Unterberg Towbin, UBS, Robertson Stephens and Wells Fargo. Hany received a BA in East Asian Studies and Economics from Columbia University and an MBA from the Wharton School, University of Pennsylvania.
Pangaea, along with many other AIDS organizations in the U.S. and internationally, has signed a letter supporting FDA review of an HIV medicine that has been studied for Pre-Exposure Prophylaxis (PrEP). A number of trials are being conducted around the world to assess whether HIV-negative people at risk of HIV can reduce their risk of becoming infected by taking antiretroviral medicines.
Results of one such trial were announced at the end of last year, and found that the HIV infection rate in HIV-negative gay men who were given a daily preventative pill containing two HIV drugs was reduced by 44 percent compared to men given a placebo.